Deutsche Bank’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,096
| Closed | -$49.5K | – | 3505 |
|
|
2024
Q1 | $49.5K | Hold |
1,096
| – | – | ﹤0.01% | 3352 |
|
|
2023
Q4 | $51.7K | Buy |
1,096
+942
| +612% | +$44.5K | ﹤0.01% | 3372 |
|
|
2023
Q3 | $6.23K | Sell |
154
-693
| -82% | -$28.1K | ﹤0.01% | 3533 |
|
|
2023
Q2 | $90.2K | Sell |
847
-882
| -51% | -$93.9K | ﹤0.01% | 3307 |
|
|
2023
Q1 | $516K | Buy |
1,729
+218
| +14% | +$65.1K | ﹤0.01% | 2465 |
|
|
2022
Q4 | $519K | Sell |
1,511
-68
| -4% | -$23.4K | ﹤0.01% | 2426 |
|
|
2022
Q3 | $298K | Sell |
1,579
-101
| -6% | -$19.1K | ﹤0.01% | 2681 |
|
|
2022
Q2 | $354K | Buy |
1,680
+141
| +9% | +$29.7K | ﹤0.01% | 2787 |
|
|
2022
Q1 | $514K | Sell |
1,539
-250
| -14% | -$83.5K | ﹤0.01% | 2714 |
|
|
2021
Q4 | $582K | Sell |
1,789
-267
| -13% | -$86.9K | ﹤0.01% | 2722 |
|
|
2021
Q3 | $999K | Buy |
2,056
+542
| +36% | +$263K | ﹤0.01% | 2600 |
|
|
2021
Q2 | $704K | Buy |
1,514
+24
| +2% | +$11.2K | ﹤0.01% | 2993 |
|
|
2021
Q1 | $1.03M | Sell |
1,490
-56
| -4% | -$38.7K | ﹤0.01% | 2630 |
|
|
2020
Q4 | $1.14M | Buy |
1,546
+264
| +21% | +$195K | ﹤0.01% | 2342 |
|
|
2020
Q3 | $890K | Buy |
1,282
+78
| +6% | +$54.2K | ﹤0.01% | 2264 |
|
|
2020
Q2 | $1.02M | Buy |
1,204
+228
| +23% | +$193K | ﹤0.01% | 2204 |
|
|
2020
Q1 | $349K | Sell |
976
-2
| -0.2% | -$715 | ﹤0.01% | 2654 |
|
|
2019
Q4 | $227K | Buy |
978
+872
| +823% | +$202K | ﹤0.01% | 3103 |
|
|
2019
Q3 | $10K | Sell |
106
-178
| -63% | -$16.8K | ﹤0.01% | 4269 |
|
|
2019
Q2 | $49K | Buy |
+284
| New | +$49K | ﹤0.01% | 4302 |
|
|
2019
Q1 | – | Sell |
-322
| Closed | -$19K | – | 4740 |
|
|
2018
Q4 | $19K | Buy |
322
+128
| +66% | +$7.55K | ﹤0.01% | 4408 |
|
|
2018
Q3 | $24K | Buy |
+194
| New | +$24K | ﹤0.01% | 4571 |
|